TY  - JOUR
AU  - Márk, László
AU  - Fülöp, Péter
AU  - Lőrincz, Hajnalka
AU  - Dani, Győző
AU  - Tajtiné, Krisztina Fazekas
AU  - Thury, Attila
AU  - Paragh, György
TI  - The Evaluation of Lipid-Lowering Treatment in Patients with Acute Coronary Syndrome in a Hungarian Invasive Centre in 2015, 2017, and during the COVID-19 Pandemic—The Comparison of the Achieved LDL-Cholesterol Values Calculated with Friedewald and Martin–Hopkins Methods
JF  - JOURNAL OF CLINICAL MEDICINE
J2  - J CLIN MED
VL  - 13
PY  - 2024
IS  - 12
SP  - 3398
SN  - 2077-0383
DO  - 10.3390/jcm13123398
UR  - https://m2.mtmt.hu/api/publication/35061032
ID  - 35061032
AB  - Background/Objectives: Patients with acute coronary syndrome (ACS) represent a vulnerable population. We aimed to investigate serum lipid levels of patients with ACS upon admission and during one year of the COVID-19 pandemic in a rural county hospital, and compared these findings with the data of patients with ACS in 2015 and 2017. The secondary aim of this paper was the comparison of the LDL-C values calculated with the Friedewald and Martin–Hopkins methods. Methods: A retrospective analysis of lipid-lowering data of patients treated with ACS in 2015, 2017 and in a COVID-19 year (1 April 2020–31 March 2021) was performed; the patient’s numbers were 454, 513 and 531, respectively. Results: In the COVID-19 period one year after the index event, only 42% of the patients had lipid values available, while these ratios were 54% and 73% in 2017 and in 2015, respectively. Using the Friedewald formula, in the COVID-19 era the median of LDL cholesterol (LDL-F) was 1.64 (1.09–2.30) mmol/L at six months and 1.60 (1.19–2.27) mmol/L at one year, respectively. These values were 1.92 (1.33–2.27) mmol/L and 1.73 (1.36–2.43) mmol/L using the Martin–Hopkins method (LDL-MH). The LDL-F yielded significantly lower values (15% lower at six months, p = 0.044; and 8% lower at one year, p = 0.014). The LDL-F reached the previous target of 1.8 mmol/L during the COVID-19 pandemic 36% at one year vs. 48% in 2017, and 37% in 2015. The recent target LDL-C level of 1.4 mmol/L was achieved in 22% of cases in the COVID-19 pandemic, 16% in 2015 and 19% in 2017. Conclusions: A significantly lower proportion of patients with ACS had available lipid tests during the COVID-19 pandemic. Besides the lower number of available samples, the proportion of achieved 1.4 mmol/L LDL-C target lipids was stable. More rigorous outpatient care in the follow-up period may help to improve the quality of lipid lowering treatments and subsequent secondary cardiovascular prevention. If direct LDL-C determination is not available, we prefer the LDL calculation with the Martin–Hopkins method.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Ma, W.
AU  - Liu, W.
AU  - Mu, J.
TI  - Influencing Mechanism of Large-dose of Atorvastatin in Serum Visfatin, MMP-9, and Blood Fat Levels of Patients with Acute Coronary Syndromes
JF  - CELLULAR AND MOLECULAR BIOLOGY
J2  - CELL MOL BIOL
VL  - 69
PY  - 2023
IS  - 3
SP  - 118
EP  - 123
PG  - 6
SN  - 0145-5680
DO  - 10.14715/cmb/2023.69.3.16
UR  - https://m2.mtmt.hu/api/publication/34070083
ID  - 34070083
N1  - Department of Cardiology, Qingdao Municipal Hospital, Shandong Province, Qingdao, 266071, China            
            Department of Dry Care, Qingdao Municipal Hospital (West Hospital District), Dry Care Department of Qingdao Municipal Hospital (West Hospital District), Shandong Province, Qingdao, 266011, China            
            Export Date: 20 July 2023            
            CODEN: CMBID            
            Correspondence Address: Ma, W.; Department of Cardiology, Shandong Province, China; email: qujiao7617539960@163.com
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Zhu, Ling
AU  - Cui, Qianwei
AU  - Liu, Ying
AU  - Liu, Zhongwei
AU  - Zhang, Yong
AU  - Liu, Fuqiang
AU  - Wang, Junkui
TI  - Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
JF  - MEDICAL SCIENCE MONITOR
J2  - MED SCI MONIT
VL  - 26
PY  - 2020
SN  - 1234-1010
DO  - 10.12659/MSM.925114
UR  - https://m2.mtmt.hu/api/publication/31710478
ID  - 31710478
LA  - English
DB  - MTMT
ER  -